The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on the NASDAQ Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is re-ranked annually and all securities in the index are listed on the NASDAQ Global Market or the NASDAQ Global Select Market, and meet minimum market value and share volume requirements among other criteria. The NASDAQ Biotechnology Index is the basis for the iShares NASDAQ Biotechnology IndexSM Fund. In addition, options based on the iShares
About
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. The Company is developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited, which is expected to initiate its pivotal clinical trials in 2021 for the potential treatment of rare developmental and epileptic encephalopathies (DEEs). OVID is evaluating the results of the NEPTUNE trial of OV101 (gaboxadol) for the treatment of Angelman syndrome and Fragile X syndrome. For more information on Ovid, please visit www.ovidrx.com.
Contacts
Investors and Media:
Investor Relations & Public Relations
irpr@ovidrx.com
OR
Investors:
212-600-1902
ovid@argotpartners.com
Media:
1AB
dan@1abmedia.com
Source:
2020 GlobeNewswire, Inc., source